| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
GDP-D-mannose disodium targets mannosyltransferases, enzymes that catalyze the transfer of mannose from GDP-D-mannose to acceptor molecules in the biosynthesis of glycoproteins, glycolipids, and polysaccharides. It is a substrate for these enzymes rather than an inhibitor. The compound is used in biochemical assays to study glycosylation pathways and enzyme kinetics.
|
|---|---|
| ln Vitro |
GDP-D-mannose disodium is not evaluated for biological activity as a drug; it is a biochemical reagent. As a substrate for mannosyltransferases, it is used in enzyme assays to measure mannosyltransferase activity. The compound is also used in studies of glycoprotein synthesis and carbohydrate metabolism.
|
| ln Vivo |
GDP-D-mannose disodium is not evaluated for in vivo biological activity as a drug; it is a biochemical reagent. It is not administered as a therapeutic agent. The compound is used in research on glycosylation and glycobiology.
|
| Enzyme Assay |
In vitro enzyme assays for GDP-D-mannose disodium typically involve mannosyltransferase activity assays. The compound (typically 10-1000 μM) is incubated with the enzyme, an acceptor substrate, and divalent cations (Mn2+ or Mg2+) at 37°C for 1-4 hours. The reaction product is analyzed by HPLC, mass spectrometry, or radiometric detection. GDP release can be measured using a coupled enzyme assay.
|
| Cell Assay |
There are no specific in vitro cellular assays for GDP-D-mannose disodium as a pharmacologically active compound. As a biochemical reagent, it may be added to cell culture media to study glycosylation pathways. Cells are treated with the compound (10-100 μM) for 1-24 hours, and glycoprotein glycosylation is analyzed by lectin binding or mass spectrometry.
|
| Animal Protocol |
There are no specific in vivo animal studies for GDP-D-mannose disodium as a pharmacologically active compound. As a biochemical reagent, it is not administered to animals for efficacy studies. The compound is used in research on glycosylation and glycobiology.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of GDP-D-mannose disodium are not applicable, as it is a biochemical reagent rather than a drug. The compound is not intended for administration. It is a nucleotide sugar that is used in in vitro biochemical assays.
|
| Toxicity/Toxicokinetics |
The toxicity profile of GDP-D-mannose disodium is not extensively reported. As a biochemical reagent, it is not intended for human therapeutic use. The compound should be handled with care in a laboratory setting. No specific toxicity data are reported.
|
| References | |
| Additional Infomation |
GDP-D-mannose disodium (CAS 103301-73-1) is a nucleotide sugar that serves as a donor substrate for mannosyltransferases in glycoprotein and glycolipid biosynthesis. It has a molecular formula of C16H23N5Na2O16P2 and a molecular weight of 633.31. The compound is used in research on glycosylation, glycobiology, and carbohydrate metabolism. It is available for research purposes only.
|
| Molecular Formula |
C16H23N5O16P2-2.2[NA+]
|
|---|---|
| Molecular Weight |
649.30492
|
| Exact Mass |
649.041
|
| CAS # |
103301-73-1
|
| PubChem CID |
136239907
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
41
|
| Complexity |
1040
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XOAGKSFNHBWACO-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/C16H25N5O16P2.2Na/c17-16-19-12-6(13(28)20-16)18-3-21(12)14-10(26)8(24)5(34-14)2-33-38(29,30)37-39(31,32)36-15-11(27)9(25)7(23)4(1-22)35-15;;/h3-5,7-11,14-15,22-27H,1-2H2,(H,29,30)(H,31,32)(H3,17,19,20,28);;/q;2*+1/p-2
|
| Chemical Name |
disodium;[[5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~125 mg/mL (~192.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5401 mL | 7.7006 mL | 15.4012 mL | |
| 5 mM | 0.3080 mL | 1.5401 mL | 3.0802 mL | |
| 10 mM | 0.1540 mL | 0.7701 mL | 1.5401 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
